Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine
/in Dendritic Cells, Hyperthermia, International PublicationsEnhanced T-cell activation by immature dendritic cells loaded with HSP70-expressing heat-killed melanoma cells
/in Dendritic Cells, Hyperthermia, International PublicationsTherapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL
/in Dendritic Cells, International PublicationsImmunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells
/in Dendritic Cells, Hyperthermia, International PublicationsHarnessing dendritic cells to generate cancer vaccines
/in Dendritic Cells, International PublicationsMassive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer
/in Dendritic Cells, Hypernephroma, International PublicationsPolarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusCombining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers
/in Dendritic Cells, International PublicationsTumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo
/in Colorectal Cancer, Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer